Quick Answer: Weakness on semaglutide typically results from reduced caloric intake due to appetite suppression, gastrointestinal side effects causing dehydration and electrolyte imbalances, and rapid weight loss rather than direct medication toxicity
(To put these numbers in context, consider that the federal government now spends about $145 billion a year on the entire Part D program.) Its likely that all people enrolled in Part D would have to pay higher monthly premiums if Medicare were to cover weight-loss injections, Baig and coauthors write
The medication creates favourable conditions for lifestyle changes but cannot overcome poor dietary choices or sedentary behaviour
Battle of the bowl Another issue with GLP-1 drugs is that they can cause intense gastrointestinal struggles
Constipation: drink more water and eat fiber-rich foods
For patients and clinicians, this matters because it changes how we think about outcomes